Eugia remains under FDA scrutiny as the unit of Indian drugmaker Aurobindo has received its fifth Form 483 since December.

When Bayer unveiled a restructuring in January, the company didn’t provide specifics on the number of planned job cuts. | ...

Boehringer Ingelheim has enlisted support for its attempt to prise AbbVie’s fingers off the Humira money faucet, ...

In time for Mother’s Day, Genentech released a new Vabysmo ad suggesting that a great way to repay your mother for her years ...

Social media are full of so-called wellness “hacks” that range from the weird but harmless to the downright damaging—and ...

In the global phase 3 trial SCORPIO-HR, once-daily ensitrelvir—which goes by the brand name Xocova in Japan and falls into ...

In two months, countries from around the world will send athletes to France to compete in the 2024 Summer Olympics. But this week in Paris is all about lighting the torch for big business. | Sanofi ...

After Johnson & Johnson's consumer healthcare spinoff last year—and its subsequent reduction in holdings in the new ...

Another attempt at improving upon AstraZeneca’s Imfinzi in stage 3, unresectable non-small cell lung cancer (NSCLC) has gone ...

As patients increasingly drive their own healthcare journeys, many rely on educational resources to figure out what actions ...

Right after an industry survey suggested that switching away from Chinese CDMOs could take biopharma companies up to eight ...

Roche’s long-awaited challenge to Regeneron’s dominance in the ophthalmology market may soon be coming to a head, according ...